PBSV · Pharma-Bio Serv, Inc.
Pharma-Bio Serv Inc (PBSV)
What's happening
- PBSV is up 27.61% today, trading at $0.54. — Live quote
- Reports earnings on 2026-09-14, 11 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $0.01 actual vs. $0.03 estimated (-67.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 11.8% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +16.6%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 0.7%. Finnhub fundamentals ↗
- Trailing P/E is 201.1, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-07-22; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PBSV
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Apr '26 | Jan '26 | Jul '25 | Apr '25 | Jan '25 | Jul '24 | Apr '24 | Jan '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M | $2.3M | $2.0M | $2.4M | $2.5M | $2.4M | $2.4M | $2.4M |
| Gross profit | $902.0K | $722.4K | $574.3K | $818.7K | $768.1K | $635.4K | $618.5K | $535.6K |
| Operating income | $144.7K | -$94.5K | -$313.9K | -$98.3K | -$92.2K | -$381.8K | -$313.4K | -$438.3K |
| Net income | $233.0K | $32.9K | -$204.2K | $95.4K | $8.5K | -$309.2K | -$213.8K | -$270.7K |
| EPS (diluted) | $0.01 | $0.00 | $0.01 | $0.00 | $0.00 | $0.01 | $-0.01 | $-0.01 |
| EPS (basic) | — | — | — | — | — | — | — | — |
| Operating margin | $5 | -$4 | -$16 | -$4 | -$4 | -$16 | -$13 | -$18 |
| Net margin | $9 | $1 | -$10 | $4 | $0 | -$13 | -$9 | -$11 |
Balance sheet
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $11.5M | $13.5M | $13.7M | $13.6M | $13.9M | $16.1M | $16.3M | $16.3M |
| Total liabilities | $1.0M | $3.3M | $1.7M | $1.7M | $1.8M | $4.1M | $2.6M | $2.6M |
| Stockholders' equity | $10.5M | $10.2M | $11.9M | $11.9M | $12.1M | $12.0M | $13.7M | $13.7M |
| Total current assets | $11.3M | $13.3M | $13.4M | $13.2M | $13.4M | $15.5M | $15.7M | $15.9M |
| Total current liabilities | $1.0M | $3.3M | $1.7M | $1.7M | $1.8M | $3.4M | $1.9M | $1.9M |
| Cash & equivalents | — | — | — | — | — | — | — | — |
| Marketable securities (current) | $6.7M | $4.8M | $7.5M | $6.8M | $8.3M | $5.1M | $6.0M | $6.3M |
| Accounts receivable | $2.7M | $2.7M | $2.4M | $2.0M | $2.7M | $2.7M | $2.5M | $2.6M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $92.4K | $103.7K | $116.1K | $131.5K | $145.2K | $159.8K | $169.3K | $18.2K |
| Other non-current assets | $120.8K | $120.8K | $120.8K | $225.6K | $225.6K | $225.6K | $225.6K | $125.6K |
| Accounts payable | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $2.4K | $2.4K | $2.4K | $2.4K | $2.4K | $2.4K | $2.4K | $2.4K |
| Retained earnings | $9.1M | $8.8M | $10.5M | $10.5M | $10.7M | $10.6M | $12.4M | $12.3M |
| Accumulated other comprehensive income (loss) | $255.0K | $280.4K | $278.0K | $285.6K | $282.9K | $243.9K | $262.4K | $253.3K |
Cash flow
| Line item | Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Jan '25 | Oct '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$365.3K | -$390.1K | $214.6K | $236.5K | -$301.6K | -$429.5K | — | -$1.3M |
| Investing cash flow | -$1.9M | $2.8M | -$2.5M | $1.6M | -$3.2M | $988.3K | — | $3.4M |
| Financing cash flow | -$1.7M | -$1.7K | -$1.8M | -$5.0K | -$1.7M | $0 | — | -$1.7M |
| Free cash flow | -$367.6K | -$392.6K | $208.0K | $234.5K | -$305.8K | -$429.5K | — | -$1.5M |
| Capital expenditures | $2.3K | $2.4K | $6.6K | $2.0K | $4.3K | $0 | — | $158.9K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $8.6K | $8.6K | $24.4K | $10.0K | $10.0K | $10.7K | — | $32.7K |
| Change in accounts receivable | $78.0K | $277.1K | -$390.0K | -$675.4K | -$62.5K | $186.4K | — | $104.2K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Dividends paid | $1.7M | — | $1.7M | $0 | $1.7M | — | $1.7M | $0 |
| Share repurchases | $709 | $1.7K | $31.4K | $5.0K | $17.2K | $0 | — | $4.1K |
Income statement
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 |
|---|---|---|---|---|---|
| Revenue | $9.0M | $9.5M | $17.0M | $19.4M | $20.1M |
| Gross profit | $2.9M | $2.5M | $5.1M | $4.9M | $5.4M |
| Operating income | -$637.7K | -$1.3M | $1.1M | $1.2M | -$3.9M |
| Net income | -$100.5K | -$777.6K | $1.3M | $1.0M | -$2.1M |
| EPS (diluted) | $-0.00 | $-0.03 | $0.06 | — | — |
| EPS (basic) | — | — | — | — | — |
| Operating margin | -$7 | -$14 | $7 | $6 | -$19 |
| Net margin | -$1 | -$8 | $8 | $5 | -$10 |
Balance sheet
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 |
|---|---|---|---|---|---|
| Total assets | $13.7M | $16.3M | $19.9M | $20.7M | $23.9M |
| Total liabilities | $1.7M | $2.6M | $3.8M | $4.1M | $5.0M |
| Stockholders' equity | $11.9M | $13.7M | $16.1M | $16.6M | $18.9M |
| Total current assets | $13.4M | $15.7M | $19.4M | $19.9M | $22.8M |
| Total current liabilities | $1.7M | $1.9M | $2.2M | $2.1M | $2.7M |
| Cash & equivalents | — | — | — | $14.5M | $17.5M |
| Marketable securities (current) | $7.5M | $6.0M | $4.5M | $0 | — |
| Accounts receivable | $2.4M | $2.5M | $3.9M | $5.0M | $4.6M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $116.1K | $169.3K | $32.8K | $73.7K | $105.5K |
| Other non-current assets | $120.8K | $225.6K | $111.7K | $130.9K | $353.4K |
| Other non-current liabilities | — | — | — | — | — |
| Common stock & paid-in capital | $2.4K | $2.4K | $2.4K | $2.3K | $2.3K |
| Retained earnings | $10.5M | $12.4M | $14.9M | $15.3M | $17.7M |
| Accumulated other comprehensive income (loss) | $278.0K | $262.4K | $210.3K | $238.2K | $144.5K |
Cash flow
| Line item | Oct '25 | Oct '24 | Oct '23 | Oct '22 | Oct '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$214.9K | -$566.7K | $1.9M | $592.5K | $804.8K |
| Investing cash flow | -$1.5M | -$1.4M | -$4.2M | -$19.3K | $1.3M |
| Financing cash flow | -$1.8M | -$1.7M | -$1.8M | -$3.5M | -$1.8M |
| Free cash flow | -$221.5K | -$726.4K | $1.9M | $573.2K | $794.0K |
| Capital expenditures | $6.6K | $159.7K | $7.3K | $19.3K | $10.8K |
| Depreciation & amortization | — | — | — | $51.1K | $72.7K |
| Share-based compensation | $35.1K | $47.5K | $45.1K | $71.6K | $56.2K |
| Change in accounts receivable | -$203.6K | -$1.5M | -$1.1M | -$463.3K | $135.0K |
| Purchases of investments | — | — | $4.2M | $0 | — |
| Dividends paid | $1.7M | $1.7M | $1.7M | $3.4M | $1.7M |
| Share repurchases | $31.4K | $11.3K | $34.3K | $82.0K | $26.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PBSV as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2023-01-09 to 2026-06-09
Recent transactions
- Most recent: SPINDEL HOWARD (Reporting person) — Other acquisition/disposition of 42,504 shares on 2026-06-09.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| SPINDEL HOWARD | Reporting person | Other acquisition/disposition | 2026-06-09 | 42,504 |
| MICHEL KIRK WHEELER | Chairman | Option exercise | 2024-01-05 | 20,000 |
| WIESEN IRVING L | Reporting person | Option exercise | 2023-03-24 | 20,000 |
| Perlysky Dov | Reporting person | Option exercise | 2023-03-24 | 20,000 |
| Sanchez Altura Victor | President and CEO | Option exercise | 2023-03-06 | 8,325 |
| LASANTA PEDRO J | Chief Financial Officer | Option exercise | 2023-03-06 | 100,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-09 | SPINDEL HOWARD | Reporting person | Other acquisition/disposition | 42,504 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 11:56 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-07-22 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-15 | 8-K | 2026-06-15 | View on SEC.gov → |
| 2026-06-15 | 10-Q | 2026-04-30 | View on SEC.gov → |
| 2026-05-15 | 8-K | 2026-05-15 | View on SEC.gov → |
| 2026-03-17 | 8-K | 2026-03-17 | View on SEC.gov → |
| 2026-03-17 | 10-Q | 2026-01-31 | View on SEC.gov → |
| 2026-01-29 | 8-K | 2026-01-29 | View on SEC.gov → |
| 2026-01-29 | 10-K | 2025-10-31 | View on SEC.gov → |
| 2026-01-14 | 4 | 2026-01-10 | View on SEC.gov → |
| 2026-01-14 | 4 | 2026-01-10 | View on SEC.gov → |
| 2026-01-14 | 4 | 2026-01-10 | View on SEC.gov → |
| 2026-01-14 | 4 | 2026-01-10 | View on SEC.gov → |
Recent news
Headlines about PBSV (Pharma-Bio Serv, Inc.). Links open the publisher — we don’t host full articles.
-
PBSV is a Small Stock Worth a Look
Yahoo Finance · 2026-06-16 -
Pharma-Bio Serv reports Q2 results
Seeking Alpha · 2026-06-15 -
Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2026
Yahoo Finance · 2026-06-15 -
PBSV Showing Improved Operations and Strong Dividend
Yahoo Finance · 2026-03-18 -
Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026
Yahoo Finance · 2026-03-17
No headlines in this category right now — try “All”.